Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + bevacizumab + pemetrexed + carboplatin
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a potential combination therapy consisting of cadonilimab (a bispecific antibody targeting PD-1 and CTLA-4), bevacizumab (an anti-VEGF monoclonal antibody), and chemotherapy agents pemetrexed and carboplatin. While clinical trials (like COMPASSION-16) have studied cadonilimab with platinum-based chemotherapy (including carboplatin) and bevacizumab for recurrent or metastatic cervical cancer, the specific four-drug combination including pemetrexed is not clearly documented in the available data. The combination aims to leverage multiple mechanisms: immune checkpoint inhibition (cadonilimab), anti-angiogenesis (bevacizumab), and cytotoxic effects (pemetrexed and carboplatin).
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DHFR (Dihydrofolate reductase)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFA (Vascular endothelial growth factor A)DNA
Beyond the preview
Go deeper on cadonilimab + bevacizumab + pemetrexed + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + bevacizumab + pemetrexed + carboplatin.